The data of Phase III trial of Bharat Biotech’s corona vaccine ‘Covaxin’ has come out. Covaccine has been found to be 77.8 percent effective in the third phase. According to the report of a leading news agency, Bharat Biotech submitted the data of the third phase of its vaccine to the Drug Controller General of India (DCGI) only last week. On which an important review meeting of the Subject Expert Committee (SEC) has been held today.
According to the report, in this review meeting the data of Phase III trial of Covaccine has been approved. The Phase III trial of Covaxin was done on 25,800 people. In which it was studied how effective this vaccine is against corona infection.
Covaxin shows 77.8 % efficacy in phase 3 trial data in review by subject expert committee (SEC): Sources
— ANI (@ANI) June 22, 2021
This data from the third phase of the vaccine has not yet been fully published in an internationally recognized, peer-reviewed journal. Bharat Biotech said earlier this month that after submitting the data to DCGI, this data would be published within a time frame of about three months.
Data from the third phase of the vaccine can also be submitted to the World Health Organization (WHO) after getting the approval of the SEC. Let us tell you that Covaccine is a completely indigenous vaccine. It has been developed by Bharat Biotech in association with the Indian Council of Medical Research (ICMR).